NO943101L - 2,6-metano-2H-kinolizinderivat som 5-HT3-reseptorantagonist - Google Patents
2,6-metano-2H-kinolizinderivat som 5-HT3-reseptorantagonistInfo
- Publication number
- NO943101L NO943101L NO943101A NO943101A NO943101L NO 943101 L NO943101 L NO 943101L NO 943101 A NO943101 A NO 943101A NO 943101 A NO943101 A NO 943101A NO 943101 L NO943101 L NO 943101L
- Authority
- NO
- Norway
- Prior art keywords
- treatment
- methano
- receptor antagonist
- quinolizine derivative
- hallucinatory
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/12—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains three hetero rings
- C07D471/18—Bridged systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/08—Drugs for disorders of the alimentary tract or the digestive system for nausea, cinetosis or vertigo; Antiemetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/04—Centrally acting analgesics, e.g. opioids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/24—Antidepressants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/26—Psychostimulants, e.g. nicotine, cocaine
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Veterinary Medicine (AREA)
- Engineering & Computer Science (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Animal Behavior & Ethology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Biomedical Technology (AREA)
- Neurosurgery (AREA)
- Neurology (AREA)
- Psychiatry (AREA)
- Pain & Pain Management (AREA)
- Hospice & Palliative Care (AREA)
- Otolaryngology (AREA)
- Epidemiology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP92400474 | 1992-02-24 | ||
| PCT/US1993/000880 WO1993017019A1 (en) | 1992-02-24 | 1993-02-03 | 2,6-methano-2h-quinolizin derivative as 5-ht3-receptor antagonist |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| NO943101L true NO943101L (no) | 1994-08-23 |
| NO943101D0 NO943101D0 (no) | 1994-08-23 |
Family
ID=8211614
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| NO943101A NO943101D0 (no) | 1992-02-24 | 1994-08-23 | 2,6-metano-2H-kinolizinderivat som 5-HT3-reseptorantagonist |
Country Status (14)
| Country | Link |
|---|---|
| EP (1) | EP0628043A1 (de) |
| JP (1) | JPH07504192A (de) |
| KR (1) | KR100287933B1 (de) |
| AU (1) | AU675060B2 (de) |
| CA (1) | CA2130563C (de) |
| FI (1) | FI105917B (de) |
| HU (1) | HU216831B (de) |
| IL (1) | IL104821A (de) |
| MX (1) | MX9300948A (de) |
| NO (1) | NO943101D0 (de) |
| NZ (1) | NZ249346A (de) |
| TW (1) | TW226374B (de) |
| WO (1) | WO1993017019A1 (de) |
| ZA (1) | ZA931146B (de) |
Families Citing this family (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2000048597A1 (en) | 1999-02-18 | 2000-08-24 | Novartis Ag | Systemic use of 5-ht3 receptor antagonists against rheumatic inflammatory processes |
| US8518962B2 (en) | 2005-03-07 | 2013-08-27 | The University Of Chicago | Use of opioid antagonists |
| US8524731B2 (en) | 2005-03-07 | 2013-09-03 | The University Of Chicago | Use of opioid antagonists to attenuate endothelial cell proliferation and migration |
| US9662325B2 (en) | 2005-03-07 | 2017-05-30 | The University Of Chicago | Use of opioid antagonists to attenuate endothelial cell proliferation and migration |
| CN101171010B (zh) | 2005-03-07 | 2014-09-17 | 芝加哥大学 | 阿片样物质拮抗剂用于减少内皮细胞增殖和迁移的用途 |
Family Cites Families (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| ES2080727T3 (es) * | 1988-02-23 | 1996-02-16 | Merrell Pharma Inc | Uso de quinolizina y derivados de quinolizinona en la fabricacion de medicamentos. |
| EP0517984A1 (de) * | 1991-06-11 | 1992-12-16 | Merrell Dow Pharmaceuticals Inc. | Amidanaloge-Derivate von methanoverbrückten Chinolizinen |
-
1993
- 1993-02-03 KR KR1019940702945A patent/KR100287933B1/ko not_active IP Right Cessation
- 1993-02-03 WO PCT/US1993/000880 patent/WO1993017019A1/en active IP Right Grant
- 1993-02-03 NZ NZ249346A patent/NZ249346A/en not_active IP Right Cessation
- 1993-02-03 CA CA002130563A patent/CA2130563C/en not_active Expired - Lifetime
- 1993-02-03 HU HU9402436A patent/HU216831B/hu unknown
- 1993-02-03 EP EP93904797A patent/EP0628043A1/de not_active Withdrawn
- 1993-02-03 JP JP5514868A patent/JPH07504192A/ja active Pending
- 1993-02-03 AU AU36034/93A patent/AU675060B2/en not_active Expired
- 1993-02-18 ZA ZA931146A patent/ZA931146B/xx unknown
- 1993-02-19 TW TW082101189A patent/TW226374B/zh not_active IP Right Cessation
- 1993-02-22 IL IL10482193A patent/IL104821A/xx not_active IP Right Cessation
- 1993-02-22 MX MX9300948A patent/MX9300948A/es unknown
-
1994
- 1994-08-23 FI FI943872A patent/FI105917B/fi not_active IP Right Cessation
- 1994-08-23 NO NO943101A patent/NO943101D0/no unknown
Also Published As
| Publication number | Publication date |
|---|---|
| ZA931146B (en) | 1993-09-14 |
| HU216831B (hu) | 1999-09-28 |
| HUT68249A (en) | 1995-06-28 |
| IL104821A (en) | 1997-01-10 |
| KR950700297A (ko) | 1995-01-16 |
| CA2130563A1 (en) | 1993-09-02 |
| EP0628043A1 (de) | 1994-12-14 |
| FI943872A (fi) | 1994-08-23 |
| FI943872A0 (fi) | 1994-08-23 |
| IL104821A0 (en) | 1993-06-10 |
| WO1993017019A1 (en) | 1993-09-02 |
| MX9300948A (es) | 1993-08-01 |
| HU9402436D0 (en) | 1994-10-28 |
| NZ249346A (en) | 1995-10-26 |
| AU675060B2 (en) | 1997-01-23 |
| KR100287933B1 (ko) | 2001-05-02 |
| FI105917B (fi) | 2000-10-31 |
| NO943101D0 (no) | 1994-08-23 |
| AU3603493A (en) | 1993-09-13 |
| JPH07504192A (ja) | 1995-05-11 |
| TW226374B (de) | 1994-07-11 |
| CA2130563C (en) | 1997-11-11 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| AU2005202257C1 (en) | Azacyclic compounds for use in the treatment of serotonin related diseases | |
| MXPA02010550A (es) | Agonistas muscarinicos. | |
| DK0668863T3 (da) | Quinuclidinderivat som substans P-antagonist | |
| BR0012136A (pt) | Inibidores de reabsorção de norepinefrina altamente seletivos e métodos de uso dos mesmos | |
| NO990433L (no) | Nye forbindelser og blandinger for behandling av sykdommer i forbindelse med tryptase-aktivitet | |
| WO2000064441A3 (en) | Compound for use as a medicament for treatment of disorders involving bronchocontraction | |
| MA28021A1 (fr) | Dérivés de benzimidazolone à activité agoniste des récepteurs 5-HT4 | |
| EP1007556A4 (de) | Troponin untereinheiten und fragmente zur verwendung als inhibitoren der angiogenese | |
| NO20044501L (no) | [1,4] diazenino [6,7,1-IJ] kinolin-derivater som antipsykotis og antifedme-midler | |
| DK0765320T3 (da) | Benzimidazolonderivater med central dopaminerg aktivitet | |
| DK1276476T3 (da) | Anvendelse af bradykardiske midler ved behandling af sygdomme i hjertemuskulaturen i forbindelse med hypertrofi, samt hedtil ukendte lægemiddelkombinationer | |
| FI970469A0 (fi) | Bentsimidatsolijohdannaisia, joilla on dopaminerginen aktiivisuus | |
| NO943101L (no) | 2,6-metano-2H-kinolizinderivat som 5-HT3-reseptorantagonist | |
| NO991194L (no) | Kontrollert-frigj°ring doseform av [R-(Z)-<alfa>-(metoksyimino)-<alfa>-(azabisyklo[2,2,2]okt-3-yl)acetonitril monohydroklorid | |
| EA200400302A1 (ru) | Способ лечения первичной бессонницы | |
| BR9911302A (pt) | Métodos para tratar bulimia, para tratar distúrbios mediados por atividade vagal, para tratar sìndrome de intestino irritável, para tratar apnéia ou distúrbios de apnéia, para prevenir ou controlar bulimia, distúrbios mediados por atividade vagal, sìndrome de intestino irritável, bradicardia ou bradiarritmia, asma, incontinência urinária, e, apnéia ou distúrbios da apnéia em um paciente | |
| WO2000076500A3 (en) | Compound for use as a medicament for treatment of disorders involving bronchocontraction | |
| NO20005223L (no) | Sammensetning for og behandling av inflammatrisk tarmsykdom ved administrering av N-acetylglucosamin i tykktarmen | |
| MXPA02006146A (es) | Uso de metabolitos bioactivos de gepirona para el tratamiento de desordenes psicologicos. | |
| NO984651L (no) | Anvendelse av benzonaftalenderivater for fremstilling av medikamenter for behandling av sykdommer i sentralnervesystemet | |
| Glasper et al. | Within-patient variability in clinical presentation of gamma-hydroxybutyrate withdrawal: a case report | |
| WO1999051216A3 (en) | 3-pyridyloxyalkylamine or aryloxyalkylamine derivatives as cholinergic agonists | |
| EP1632235A3 (de) | Verwendung von hochselektiven Norepinephrin-Aufnahme-Inhibitoren zur Behandlung von mentalen Erkrankungen | |
| NO951865L (no) | Quinuclidin-derivat som substans-P antagonist | |
| Ansseau et al. | The use of high dose lormetazepam in psychiatric in-patients |